(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 11.32% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 130.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.65%.
Alpha Teknova's revenue in 2025 is $39,801,000.On average, 8 Wall Street analysts forecast TKNO's revenue for 2025 to be $2,212,896,053, with the lowest TKNO revenue forecast at $2,110,762,389, and the highest TKNO revenue forecast at $2,298,810,377. On average, 8 Wall Street analysts forecast TKNO's revenue for 2026 to be $2,549,326,912, with the lowest TKNO revenue forecast at $2,413,095,164, and the highest TKNO revenue forecast at $2,697,870,370.
In 2027, TKNO is forecast to generate $2,960,591,556 in revenue, with the lowest revenue forecast at $2,809,050,464 and the highest revenue forecast at $3,085,689,235.